Feds Call Out Gilead's Efforts To Revise HIV Drug IP Judgment <https://www.law360.com/delaware/articles/1833108?nl_pk=8f2e5a76-bb66-462b-a05a-b234142584d6&utm_source=newsletter&utm_medium=email&utm_campaign=delaware&utm_content=2024-05-03&read_main=1&nlsidx=0&nlaidx=9> By Hannah Albarazi The U.S. Department of Justice has asked a Delaware federal judge to reject Gilead Sciences' motion to modify a judgment finding that two medications in its HIV prevention regimen directly infringe voided patents owned by the government, arguing that the pharmaceutical company's attempt to rewrite the judgment is "unnecessary as well as improper." 1 document attached | Read full article » <https://www.law360.com/delaware/articles/1833108?nl_pk=8f2e5a76-bb66-462b-a05a-b234142584d6&utm_source=newsletter&utm_medium=email&utm_campaign=delaware&utm_content=2024-05-03&read_more=1&nlsidx=0&nlaidx=9> | Save to favorites » <https://www.law360.com/delaware/articles/1833108?nl_pk=8f2e5a76-bb66-462b-a05a-b234142584d6&utm_source=newsletter&utm_medium=email&utm_campaign=delaware&utm_content=2024-05-03&read_later=1&nlsidx=0&nlaidx=9>